Kyverna Therapeutics, Inc.
KYTX
$3.78
-$0.03-0.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 211.68M | 242.65M | 285.98M | 321.59M | 346.24M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 2.65M | 5.00M | 4.62M | 3.79M | 2.59M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 214.33M | 247.65M | 290.60M | 325.37M | 348.82M |
|
|
|||||
| Total Current Assets | 214.33M | 247.65M | 290.60M | 325.37M | 348.82M |
| Net Property, Plant & Equipment | 7.58M | 8.80M | 10.66M | 11.38M | 12.51M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 4.60M | 4.20M | 3.39M | 2.44M | 1.79M |
| Total Assets | 226.51M | 260.66M | 304.65M | 339.20M | 363.12M |
|
|
|||||
| Total Accounts Payable | 9.92M | 8.47M | 4.62M | 9.93M | 4.86M |
| Total Accrued Expenses | 26.30M | 21.24M | 11.13M | 17.12M | 14.75M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 3.58M | 3.59M | 3.94M | 3.93M | 3.87M |
| Total Finance Division Other Current Liabilities | -- | -- | 14.06M | -- | -- |
| Total Other Current Liabilities | -- | -- | 14.06M | -- | -- |
| Total Current Liabilities | 39.79M | 33.29M | 33.76M | 30.99M | 23.48M |
|
|
|||||
| Total Current Liabilities | 39.79M | 33.29M | 33.76M | 30.99M | 23.48M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 2.34M | 3.35M | 4.30M | 5.21M | 6.13M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | 296.00K | -- |
| Total Liabilities | 42.13M | 36.65M | 38.06M | 36.49M | 29.61M |
|
|
|||||
| Common Stock & APIC | 534.63M | 532.17M | 530.00M | 528.59M | 525.09M |
| Retained Earnings | -350.24M | -308.16M | -263.52M | -226.03M | -191.54M |
| Treasury Stock & Other | -20.00K | -1.00K | 105.00K | 153.00K | -37.00K |
| Total Common Equity | 184.38M | 224.01M | 266.59M | 302.71M | 333.51M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 184.38M | 224.01M | 266.59M | 302.71M | 333.51M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 184.38M | 224.01M | 266.59M | 302.71M | 333.51M |
|
|
|||||